Expertise in
1
conditions

Anne Lesoin

Lille, FR 
Expertise in
1
conditions
Lille, FR 

Overview

Anne Lesoin practices practicing medicine in Lille, France.

Ms. Lesoin is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, and Ocular Toxoplasmosis.

She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Lille, France
Other Locations
3 Avenue Général Harris, Caen, 14000, France
Grenoble, France
Merignies, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Enrollment Status: Completed
Publish Date: December 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Enrollment Status: Unknown
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: AZD2014, Anastrozole
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

23 Total Publications

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Journal: Gynecologic oncology
Published: November 22, 2021

Frequently Asked Questions about Anne Lesoin

Is Anne Lesoin a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Anne Lesoin is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anne Lesoin participate in research or clinical trials?

Yes. Anne Lesoin has published 23 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Anne Lesoin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lesoin's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile